Ascelia Pharma ABOSTO:ACE -75.37%29 EBIT per Share is kr-0.57 as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,178 Biotechnology companies, Ascelia Pharma AB ranks better than 78.61% on this metric.
Ascelia Pharma AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.57.
During the past 3 years, the average EBIT per Share Growth Rate was 39.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 22.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ascelia Pharma AB's EBIT per Share or its related term are showing as below:
OSTO:ACE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -56.5 Med: -10.4 Max: 39.4
Current: 39.4
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Ascelia Pharma AB was 39.40% per year. The lowest was -56.50% per year. And the median was -10.40% per year.
OSTO:ACE's 3-Year EBIT Growth Rate is ranked better than 78.61% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs OSTO:ACE: 39.40
Ascelia Pharma AB (OSTO:ACE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ascelia Pharma AB EBIT per Share Related Terms
Ascelia Pharma AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Ascelia Pharma AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascelia Pharma AB (OSTO:ACE) has a EBIT per Share of kr-0.57 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #252 out of 1178 companies in the Biotechnology industry, placing it in the top 21.4%.
Is Ascelia Pharma AB's EBIT per Share too high?
Ascelia Pharma AB's current EBIT per Share is kr-0.57. Based on the distribution chart, Ascelia Pharma AB ranks #252 out of 1178 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascelia Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #252 out of 1178 companies for EBIT per Share. This places Ascelia Pharma AB in the top 21% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ascelia Pharma AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascelia Pharma AB's current EBIT per Share is kr-0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current EBIT per Share of kr-0.57. The current EBIT per Share is kr-0.57. Ascelia Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current EBIT per Share is kr-0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score
Get the complete analysis for OSTO:ACE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACE has been successfully added to your 
